Biogen (BIIB) Tops Q3 EPS by 37c; cuts EPS forecast
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $200.57 -2.63%
Revenue Growth %: -6.5%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
DIT, AMC, DPZ, More
Revenue Growth %: -6.5%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
DIT, AMC, DPZ, More
Join SI Premium – FREE
(Updated - November 8, 2023 7:04 AM EST)
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.36, $0.37 better than the analyst estimate of $3.99. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $14.50-$15.00, saw $15.00-16.00,
- Reflecting ~$0.75 of dilution from Reata acquisition which closed September 26, 2023
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA expects Apple to top analyst expectations on July 30
- Netflix (NFLX) Tops Q2 EPS by 1c, Offers Guidance
- B.Riley on AMC Entertainment (AMC) earnings: 'Overall, we thought this was an encouraging report'
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
